Lupin announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Sildenafil for Oral Suspension, 10 mg/mL to market a generic equivalent of Revatio for Oral Suspension, 10 mg/mL, of Viatris Specialty LLC. The product will be manufactured at Lupin’s facility in Goa, India.

 Sildenafil for Oral Suspension, 10 mg/mL (RLD Revatio) had estimated annual sales of US $ 66 million in the U.S. (IQVIA MAT December 2021).